EHMT2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL366593	1.00	19/20
SCHEMBL199314	0.60	16/20
Gliotoxin (SCHEMBL54420)	1.00	11/20
SCHEMBL199299	0.51	11/20
SCHEMBL830075	0.52	9/20
SCHEMBL830001	0.50	9/20
SCHEMBL429383	0.52	8/20
SCHEMBL429384	0.52	8/20
SCHEMBL430392	0.47	8/20
SCHEMBL1088732	0.46	8/20
SCHEMBL899551	0.62	7/20
Hydrochloric Acid (SCHEMBL900295)	0.61	7/20
SCHEMBL424718	0.52	7/20
SCHEMBL996743	0.78	5/20
Calycanthine (SCHEMBL893195)	0.43	5/20
SCHEMBL1006038	0.35	5/20
Disulfiram (SCHEMBL27213)	1.00	4/20
SCHEMBL76857	1.00	4/20
Sinefungin (SCHEMBL167609)	1.00	4/20
SCHEMBL95173	0.82	4/20

Clinical trials — most relevant to EHMT2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)	PHASE1/PHASE2	NOT_YET_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a EHMT2 binder may also engage these)

Protein	Name	Similarity
Q9Z148	—	1.000	Q9Z148 →
Q9UPV7	—	0.997	Q9UPV7 →
Q5DW34	—	0.997	Q5DW34 →
EHMT1	Histone-lysine N-methyltransferase EHMT1	0.996	landscape →
BPTF	Nucleosome-remodeling factor subunit BPTF	0.995	landscape →
Q9BQK8	—	0.995	Q9BQK8 →
Q5BIR3	—	0.995	Q5BIR3 →
Q2PFD7	—	0.995	Q2PFD7 →
Q5TKR9	—	0.994	Q5TKR9 →
Q99PI5	—	0.994	Q99PI5 →
Q96PX1	—	0.993	Q96PX1 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.993	landscape →
Q24K09	—	0.993	Q24K09 →
Q5R4R7	—	0.993	Q5R4R7 →
P10244	—	0.993	P10244 →
O43310	—	0.993	O43310 →
Q811D2	—	0.993	Q811D2 →
Q92539	—	0.993	Q92539 →
Q63553	—	0.993	Q63553 →
E9Q555	—	0.993	E9Q555 →
Q8WML3	—	0.992	Q8WML3 →
Q60700	—	0.992	Q60700 →
Q9H329	—	0.992	Q9H329 →
Q5R8X7	—	0.992	Q5R8X7 →
Q566C8	—	0.992	Q566C8 →
A7MBB4	—	0.992	A7MBB4 →
Q9JM61	—	0.992	Q9JM61 →
A7E1Z1	—	0.992	A7E1Z1 →
A6QP06	—	0.992	A6QP06 →
Q8BWQ5	—	0.992	Q8BWQ5 →